Purpose of Review Portal cavernoma cholangiopathy is a rare condition, a proper recognition of which is critical. Solid data on this condition are scarce. This review aims at updating current knowledge on its definition, manifestations, diagnosis, and management. Recent Findings A consensus has been reached to prefer the denomination portal cavernoma cholangiopathy for the bile duct irregularities associated with portal cavernoma. Such irregularities are characterized by stenosis with or without dilatation and are mostly related to the impinging on bile duct lumen by portoportal collaterals. While bile duct irregularities are found in over 80% of patients with portal cavernoma, clinical manifestations, and complications (cholecystitis and biliary stones, but rarely cholestasis) occur in only 5-35% of them. Diagnosis can be and should be based on findings at magnetic resonance cholangiography and portography. Differential diagnosis includes primary and secondary sclerosing cholangitis, and cholangiocarcinoma. Asymptomatic patients may be managed expectantly. Endoscopic procedures are to be used in the first line for complications. Combined endoscopic and surgical approaches including portosystemic shunting can be considered in refractory or recurrent cases. Summary Portal cavernoma cholangiopathy mostly is a morphologic entity which is present in a majority of patients with portal cavernoma. The minority of patients with acute biliary complications should be treated as conservatively as possible. Late consequences of chronic cholestasis appear to be rare.
Introduction
Portal cavernoma cholangiopathy is a long described entity that has received various denominations in the past [1] . This entity is characterized by the biliary changes found in association with cavernous transformation of the portal vein. A working party convened by the Indian Association for the Study of the Liver (INASL) in 2013 has recommended that the terms portal cavernoma cholangiopathy be used where those of portal biliopathy, portal hypertensive biliopathy, portal cholangiopathy, pseudo-cholangiocarcinoma, pseudosclerosing cholangitis, and portal cavernoma associated cholangiopathy had previously been employed in a context of portal cavernoma [2••] . This review focuses on data collected or systematically reviewed on this rare entity since 2010, with an emphasis on the output of the dedicated INASL 2013 working party [2••] .
Definition
The INASL 2013 working party proposed that portal cavernoma cholangiopathy be defined as "abnormalities in the extrahepatic biliary system including the cystic duct and gallbladder with or without abnormalities in the first and second generation biliary ducts in a patient with portal cavernoma" [2••] . Accordingly, it was recommended that all of the following criteria be fulfilled for a clinical diagnosis [2••] : (i) presence of a portal cavernoma; (ii) typical cholangiographic changes; and (iii) absence of other causes of these biliary changes, as further detailed below in "Diagnosis" section. 
Morphological Changes in the Bile Ducts Associated with Portal Cavernoma
The initial description of the biliary changes observed in patients with portal cavernoma was made at ERCP, mostly performed in patients with biliary manifestations [3] . These descriptions were further duplicated and extended when MR cholangiography became widely available [4] . As presented in Table 1 and illustrated in Fig. 1 , the anomalies consisted in extrahepatic strictures, intrahepatic biliary dilatation, caliber irregularity, ductal ectasia, indentations, displacement and angulations of ducts, clustering and pruning of intrahepatic ducts, and filling defects in intra and extrahepatic biliary system. A standardized nomenclature has been proposed at the INASL working party, which is as follows [2••, 3] :
Extrinsic Impressions/Indentations Smooth thumb-like impressions on the bile duct, with a nodular contour. The indentation is more than one-quarter of the width of the opacified duct. Impressions may be multiple.
Shallow Impressions/Indentation(s) Smooth non-contiguous impressions on the bile duct, less than one-quarter of ductal diameter.
Irregular Ductal Contour Fine-wavy, irregular contour of the bile duct walls due to contiguous shallow indentations, less than one-quarter of the ductal diameter.
Stenosis It is the variable length narrowing of the ductal lumen, in reference to well opacified downstream duct segment. Stenoses might be associated with upstream dilatation and may be due to extrinsic compression by collaterals or intrinsic narrowing or stricturing due to mural fibrosis. Strictured bile duct segments should offer some resistance to passage of an adequately inflated extraction balloon across it and should produce a waist on non-compliant balloons inflated within the narrowed segment. Stenoses and strictures may be divided into "mild to moderate" or "severe" depending on whether the narrowed segment is > or < two-third of the diameter of adjacent normal segment.
Upstream Dilatation Proximal dilatation can be similarly classified as "mild to moderate" or "severe," depending on whether the dilated segment is between 1.5-2 and > 2 diameter of the adjacent normal duct, respectively. (vi) Filling defects: round, oval, or elongated defects in the cholangiographic image, with contrast on three or all sides. Filling defects can represent stones, prolapsing intra-luminal varices, or clots.
Bile Duct Angulation It is proposed that an angle of < 145°b etween lower and upper CBD be considered as significant.
Ectasia It is the dilated segment of biliary tree without any evident downstream obstruction. Two other classifications have been used. The first one refers to the extrahepatic and/or intrahepatic location of biliary anomalies [5] ; and the other to the degree of severity of the biliary changes: no abnormalities; grade I (irregularities or angulations of the biliary tree); grade II (indentations or strictures without dilation); and grade III (strictures with dilation; biliary dilation was considered when the intrahepatic duct was > 4 mm or when the extrahepatic duct was > 7 mm) [6••] .
Pathogenesis and Pathophysiology

Pathogenesis of Strictures and Dilatation
The best documented explanation for bile duct irregularities is an impingement of the lumen of the bile ducts by the portoportal collaterals constituting the portal cavernoma [7•] . Indeed, such collaterals (i) are known to develop early (within days) after the acute obstruction of the main portal vein; (ii) may take an important development; and (iii) develop in a large part from various preexisting venous plexuses in contact with the bile ducts, including the epicholedocal plexus of Saint and the paracholedocal plexus of Petren [8•] . Indeed, these parabiliary venous plexuses connect with the main portal vein through posterior superior pancreaticoduodenal vein, gastrocolic trunk, right gastric vein, superior mesenteric vein inferiorly, and to the intrahepatic portal vein branches superiorly [8•] . Furthermore, intracholedocal varices may develop from intramural and subepithelial plexuses, connected to the former epicholedocal and paracholedochal varices by perforating vessels [7•, 8•] . Such portal cavernoma-associated venous collaterals have been well demonstrated using vascular enhancement at computed tomography (CT), magnetic resonance (MR) angiography and cholangiography, as well as endoscopic ultrasonography [9, 10, 11•] . Cholangioscopy has also allowed for a direct view at the subepithelial endocholedochal veins [12] .
Vascular impinging on biliary lumen was initially suggested by endoscopic retrograde cholangiography findings [3] . Evidence for such a mechanism had been brought about by showing a disappearance of bile duct irregularities following [2••] portosystemic shunting [7•, 13] . Demonstration eventually came out with the confrontation of MR portographic and cholangiographic images, as illustrated in Fig. 1 [7•, 14••] .
Still it appears that not all bile duct irregularities found in patients with portal cavernoma can be shown to regress following effective decompression of the portal venous system with portal systemic shunting [15•, 16•, 17] or to correspond to extrinsic imprinting from portoportal collaterals [17] . A lack of regression following an effective decompressive surgery, however, is not a completely convincing argument for a fixed, structural component to the formation of stenosis as it is well known that venous collaterals may persist following functioning portosystemic shunts [7•, 18, 19, 20•] . It has been suggested that biliary strictures might not be constantly associated with imprinting by a large portoportal collateral [17] , although we have reported opposite findings [14••] . If real, this dissociation has raised several hypotheses, none of which has been firmly documented. A first hypothesis is that stenosis are of ischemic origin, because portal vein venous obstruction would lead to a decrease in arterial perfusion to the bile ducts [7•] . Indeed, bile duct blood perfusion is exclusively of arterial origin. In a setting of questionable relevance to portal cavernoma, the acute clamping of the main portal vein before duodenopancreatectomy in 15 patients reduced microperfusion indices for the common bile duct by 38% on average [21] which appears insufficient to explain ischemic stricture development. We did not encounter any case of biliary stenosis among 43 patients with early stage portal vein thrombosis [14••] . A second hypothesis is that collateral veins themselves can thrombose and be replaced by fibrous tissue (constituting the so-called pseudo-tumorous cavernoma) that will constrict the bile duct lumen [14••] . However, pathological confirmation of such a mechanism has not been provided, yet.
An interesting longitudinal study on 67 patients with portal cavernoma (including 22 followed from the stage of acute portal vein thrombosis) has allowed to analyze to some extent the kinetics of the development of portal cholangiopathy [6••] . From a limited amount of data retrospectively analyzed, it appears that severe cholangiopathy (i.e., with bile duct dilatation) either develop within the first year of acute portal vein thrombosis, or will not develop. These data need independent confirmation. Still they suggest that the development of large collateral in porta hepatitis in close vicinity to the bile ducts is a relatively early phenomenon that does not progress uniformly across patients.
Pathogenesis of Biliary Stones
Biliary stones are common in patients with portal cavernoma cholangiopathy. Among 29 children with portal cavernoma evaluated for a Rex procedure, the prevalence of biliary stones or sludge (10%) was 50-to 100-fold higher than expected in the pediatric population [20•] . Data available in adults also show a high prevalence of biliary stones (14 to 84%), but they are more difficult to interpret as they were mostly collected in patients with biliary symptoms and as biliary stones are more common in adults [21] . The prevalence of biliary stones in series of patients not selected on the basis of symptoms was 11% [6••] and 16% [14••] , which might be underestimated as the most sensitive techniques were not used for detection of cholelithisasis. In a recently reported prospective study using MR cholangiography, cholelithiasis, choledocholithiasis, and hepatolithiasis were seen in 28%, 14%, and 12% of patients, respectively [22•] . Studies on bile components secretion in patients or in relevant animal models of chronic extrahepatic portal vein obstruction are lacking. The observations of bile flow changes after of acute portal vein occlusion, or in the liver area corresponding to the chronic obstruction of a single right or left portal vein branch in animals [23] are not relevant to portal 
Pathophysiology of Cholestasis
The impact of bile duct irregularities on global choleresis remains ill-defined and probably highly variable from patient to patient. Indeed, whereas 75% of patients develop strictures of the bile ducts only two thirds of them appear to harbor a dilatation upstream from the strictures [6••] . Furthermore, among 34 patients with severe portal cavernoma cholangiopathy (i.e., with bile duct dilatation), only 50% had cholestasis as defined by a combined increase in serum levels of GGT and alkaline phosphatase [6••] . This proportion was similar to that of patients having cholestasis among those with stenosis without dilation or with mild irregularities of the bile ducts [6••] . Similarly, among 91 recently reported patients with significant dilatation of the bile ducts due to portal cavernoma cholangiopathy, only 57% had increased levels of serum alkaline phosphatase levels [24•] . Among 25 consecutive patients with portal cavernoma, 23 of whom had portal cholangiopathy, GGT was increased in only 52%, serum alkaline phosphatase in 20%, and serum bilirubin in 52%. Thus, laboratory evidence of cholestasis is present only in a minority of patients with portal cavernoma cholangiopathy, and only about half those with bile duct dilatation. The relative parts played partial obstruction to the bile ducts, and by elevated portal pressure or decreased portal flow in the laboratory features of cholestasis remain to be investigated, as there is evidence from studies in animals that clamping of the portal vein results in a decreased bile flow [25] .
Clinical and Laboratory Manifestations
Only 20% of patients with portal cavernoma cholangiopathy on average (5 to 38%) have been reported to harbor symptoms that could be attributed to a biliary origin [26] . As a bias towards thorough imaging evaluation of patients with symptoms is likely (and thus an increased diagnostic yield of portal cavernoma cholangiopathy), prevalence figures for symptomatic cholangiopathy might be overestimated. In a longitudinal study on the 5-year and 10-year actuarial probability of symptomatic cholangiopathy after diagnosis of chronic portal vein thrombosis was 9% and 13%, respectively [6••] . Manifestations that were elicited from history taking were present at enrolment, or occurred during follow-up have included the following: (i) cholecystitis, with or without gallstones but with collaterals in the wall of the gallbladder or cystic duct; (ii) biliary pain usually with choledochlithiasis and hepatolithiasis but occasionally without gallstones; and (iii) acute cholangitis. While a history of jaundice has been frequently elicited, increased serum bilirubin levels have been found in less than 50% of consecutive patients [6••, 14••, 24•, 26]. As mentioned above laboratory features of cholestasis have been found in approximately a quarter of the patients with portal cavernoma cholangiopathy and half the patient with a severe form thereof (i.e., with bile duct dilatation). A picture of chronic progressive cholestasis has been rarely reported, most cases of jaundice occurring in a context of biliary pain, stones, or cholangitis. For example, in a series of 39 patients surgically treated for symptomatic portal cavernoma cholangiopathy, only 15% had jaundice as the sole manifestation whereas 62% had cholangitis [16•] .
Risk factors associated with the development of symptoms have varied across studies. According to Condat et al., biliary symptoms were associated with a history of variceal bleeding, gastroesophageal varices grade greater than 1, biliary stricture with dilatation, solid tumor-like cavernoma, and a longer time between the diagnosis of portal vein thrombosis and biliary imaging [14••] . According to Llop et al., biliary symptoms were associated with bile duct dilatation and cholestatic laboratory features, not to features related to portal vein thrombosis, portal cavernoma, or portal hypertension [6••] . In the Indian subcontinent, where childhood cavernoma is common, symptomatic cholangiopathy appears to be a late complication of portal cavernoma increasing in incidence with age [24•] . However, such a relationship could not be documented in western surveys where the adult form of acquired cavernoma is most common [6••, 14] . Duration of extrahepatic portal vein obstruction, presence of gallstones, and common bile duct stones have also been suggested risk factors [2••] .
Biliary manifestations may precede or follow the uncovering of gastroesophageal varices, the occurrence of variceal bleeding, or the diagnosis of portal hypertension/ portal cavernoma [6••, 14••, 27••]. Actually, the relationship between variceal bleeding and biliary symptoms in patients with portal cavernoma cholangiopathy is difficult to analyze due to interaction with the circumstances in which a diagnosis of portal cavernoma was made, and with the availability of modern abdominal imaging procedures. Several years may elapse between diagnosis of portal cavernoma and the first symptoms of portal cavernoma cholangiopathy. In the study by Llop et al., the median time interval was 42 months after diagnosis of acute portal vein thrombosis, and 118 months after the diagnosis of portal cavernoma [6••] .
Long-term outcome in patients with portal cavernoma cholangiopathy has been scarcely studied. A recently reported retrospective study addressed this issue in 57 selected Indian patients with a particularly severe form of the disease (a combination of bile duct dilatation and no vessels in the portal venous system available for portosystemic shunting) [24•] . The median duration of symptoms of extrahepatic portal venous obstruction was 11 years. The median follow-up was 7 years. Eleven of 57 (19.3%) patients with cholangiopathy had jaundice, 38 (66.7%) had variceal bleed, and 9 developed transient ascites after variceal bleed. None of the patients developed encephalopathy. The median duration from any index symptom to onset of symptomatic cholangiopathy was 7 years. In patients presenting with variceal bleed, the median duration to symptomatic cholangiopathy was 12 (5-24) years.
Diagnosis
There is a consensus that a diagnosis of portal cavernomarelated cholangiopathy should be established on three simultaneous arguments [2••] : (i) presence of a portal cavernoma; (ii) typical cholangiographic changes; and (iii) absence of other causes of these biliary changes. As discussed above, a diagnosis of portal cavernoma cholangiopathy can be discussed before or after the diagnosis of portal cavernoma has been made.
When the cavernoma is already known, a diagnosis of portal cavernoma cholangiopathy is now easy to make with a combined MR portography and cholangiography [2••] . The challenge is then to correctly ascribe the clinical manifestations to a biliary origin. In particular, differentiation of biliary pain from episodes of intestinal ischemia or recurrent splanchnic venous thrombosis is of importance and can be mostly based on imaging findings.
When the cavernoma is not yet known at the time when manifestations raise attention, the main consideration is for differential diagnosis with other causes of multifocal irregularities of the bile ducts (Table 2) [2••], including primary sclerosing cholangitis and other causes of cholangitis (autoimmune cholangitis, eosinophilic cholangitis, bacterial cholangitis complicating hepatolithiasis, etc.), ischemic cholangiopathy complicating various medical and instrumental interventions, or systemic disorders [28] . The key features for the discussion are the correct identification of the cavernoma, which is easy at ultrasound, CT, or MR angiography. Still, it may be extremely difficult to differentiate portal cavernoma cholangiopathy from portal vein obstruction complicating an extrahepatic cholangiocarcinoma, or from a combination of primary sclerosing cholangitis and long standing portal vein thrombosis in a patient with inflammatory bowel disease. A meticulous analysis of the relationship between bile duct stenoses and portoportal collaterals is needed. In these specific contexts, the additional information provided by endoscopic ultrasonography with an experienced operator is most valuable [11•] .
Management
There is a general consensus that only those patients with symptomatic portal cavernoma cholangiopathy be considered for treatment [2••, 27 ••], mostly because symptoms are uncommon and treatment procedures are not without drawbacks. Accordingly, emphasis has been placed on a thorough discussion of the symptoms and the ascertainment of their relationship to portal cavernoma, before deciding to proceed to treatment [2••] . Actually, "the label of symptomatic portal cavernoma cholangiopathy should be applied only on clinical grounds, i.e., to patients with biliary pain, cholestatic jaundice, and/or cholangitis due to either choledocholithiasis, choledochal stenosis, or both" [2••] . This recommendation is grounded in part on the efficacy of the available procedures to control momentarily the acute manifestations of portal cavernoma cholangiopathy, should they occur. Isolated anomalies of liver function tests are not regarded as symptoms of portal cavernoma cholangiopathy [2••] .
Ideally, treatment strategy could be oriented by the mechanisms that give rise to symptoms: stones, strictures, or both [27••] . However, it is often difficult in clinical practice to ascertain which of stones and strictures are the chicken or the egg. Furthermore, a lack of evidence for biliary stones at imaging following symptoms is not full evidence against the presence of stones having caused symptoms while they passed.
Two main options are available for symptomatic portal cavernoma: biliary clearance/drainage and portosystemic shunting, both of which have been discussed in depth in recent systematic reviews [2••, 27••].
Endoscopic Approach
The endoscopic approach comprises sphincterotomy, with CBD stone removal if present, stricture dilatation with or Hemobilia has been reported in 24 procedures. It has been claimed that hemobilia may be common due to trauma to endocholedochal varices when using balloon or Dormia Basket [27••] . However, sphincterotomy has not shown to be associated with increased bleed rates in portal cavernoma cholangiopathy and use of Dormia baskets and balloon extractors has been shown to be safe. Hemobilia can be managed conservatively in most cases and is not more troublesome than in patients without cavernoma, as reviewed by Dhiman et al. [2••] .
Cholangitis was reported after 53 procedures in these 114 patients. However, it is not clear to what extent this incidence is higher in patients with portal cavernoma cholangiopathy than in other patients submitted to endoscopic retrograde cholangiography [27••] . Furthermore, cholangitis was often not directly related to the endoscopic treatment but rather to recurrence of sludge or stones inside the biliary stent, which could be treated with stent exchange. Sepsis was observed in three cases. Mortality directly related to endoscopic treatment was 0%, but one patient died from secondary biliary cirrhosis and one from cholangitis, both having developed despite multiple stent placements during the treatment period [27••] .
The reported experience using the transhepatic route to the bile ducts is too scarce to merit any comment.
Prolonged administration of ursodeoxycholic acid has been reported as successful when used as a complement to endoscopic therapy in patients with stone or symptom recurrence after initial clearance. These uncontrolled data are difficult interpret [2••, 27••] .
Surgical Approach to Biliary Strictures/Stones
According to the systematic review by Franceschet et al., 16 reported patients underwent biliary surgery (including biliodigestive anastomosis, cholecystectomy, and choledocotomy) as a first or second line procedure [27••] . When surgical biliary anastomosis was used as a first line therapy, a complementary approach was needed in 30% of patients [27••] . Four patient deaths were reported among patients undergoing biliodigestive anastomosis as a first-line treatment [27••] . The risk of massive perioperative bleeding in patients without prior portosystemic shunting has been well documented [15•, 28] .
Portosystemic Shunting and Devascularization
Surgical and to a much lesser extent TIPS have been used to decompress the portal venous system with a double aim: to prevent recurrent bleeding related to portal hypertension and to relieve the biliary obstruction by flattening portoportal collaterals. Overall, PSS was performed in 138 patients (including 7 with splenectomy). Among patients receiving portosystemic shunting as first-line treatment of portal cavernoma cholangiopathy, 64% were relieved from biliary symptoms [27••] . The others required a complementary surgical or endoscopic approach to biliary clearance. Within the highly variable follow-up period, no death have been reported after surgical portosystemic shunting [27••] .
Devascularization, with or without splenectomy, has been performed in 19 patients usually when a portosystemic shunt was not feasible because of extensive thrombosis of the portal venous system [27••] . Although a favorable outcome of biliary involvement has been reported, this small sample size does not allow reaching any conclusion on the value of this procedure primarily oriented towards the prevention of recurrent bleeding through a non-decompressive approach.
Treatment Algorithm
Several treatment algorithms have been proposed, which have much in common [2••, 29, 30] .
The first recommended step is rapid implementation of an endoscopic approach to relieve biliary obstruction and biliary stones. An exception to this is acute cholecystitis, with or without gallstones where surgical cholecystectomy vs a combination of medical therapy and percutaneous drainage followed by subsequent cholecystectomy must be discussed.
Once resolution of clinical manifestations has been achieved, there are little data to help in choosing whether portosystemic shunting or surgical or endoscopic biliary clearance/drainage should be used first. Advances and increased experience in the medical and endoscopic treatment of gastroesophageal varices on the one hand, and benign biliary strictures/biliary stones on the other hand favor a nonsurgical approach. In support of this approach are the favorable longterm results achieved in patients with severe portal cavernoma cholangiopathy without shuntable veins [24•] . After a median follow-up of 7 years, 13 of 57 patients became symptomatic and only 5 experienced ascites, jaundice, or variceal bleeding. Thirteen received endoscopic treatment at least once and 9 at multiple occasions. Only 1 patient died from liver failure, 24 years after presentation with portal cavernoma.
The drawbacks of surgical portosystemic shunting include, besides the risk for portosystemic encephalopathy, the need for patent large splenic or superior mesenteric vein, which is lacking in many patients; an unknown risk of secondary shunt thrombosis; and a rate of clinical success on biliary manifestation not exceeding 65%. It is universally recommended that surgical approach to biliary drainage/clearance be considered only after portosystemic shunting that fails to be followed by relief of biliary manifestations. Splenectomy and devascularization are not considered part of the management for portal cavernoma cholangiopathy, although they may be considered for other reasons.
Therefore, in clinical practice, the decision to refer the patient for portosystemic shunting will usually be made by considering (i) whether shuntable veins are present; (ii) manifestations have been rapidly and completely controlled with firststep endoscopic therapy; (iii) endoscopic/pharmacologic treatment for prevention of gastrointestinal bleeding is suboptimal; and (iv) biliary manifestations recur rapidly despite adequate endoscopic management, including calibration of the bile ducts with biliary stents that are appropriately replaced.
Conclusion
Portal cavernoma cholangiopathy mostly is a morphologic entity which is present in a majority of patients with portal cavernoma, irrespectively from the severity of portal hypertension. The minority of patients with acute biliary complications should be treated as conservatively as possible. A large proportion of this complication appear to arise from biliary stones. Late consequences of chronic cholestasis appear to be rare.
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